Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The p53-deficient mouse: a model for basic and applied cancer studies

L A Donehower1

  • 1Division of Molecular Virology, Baylor College of Medicine, Houston, TX 77030, USA.

Seminars in Cancer Biology
|October 1, 1996
PubMed
Summary

Gene targeting in mice created a p53 model for Li-Fraumeni syndrome. These p53-deficient mice are crucial for studying cancer progression and evaluating potential cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma.

Oncogene·2015
Same author

Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.

Oncogene·2011
Same author

Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.

Oncogene·2010
Same author

Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines.

Mutation research·2003
Same author

Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.

Toxicologic pathology·2001
Same author

The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.

Toxicologic pathology·2001

Area of Science:

  • Genetics and Genomics
  • Cancer Biology
  • Animal Models

Background:

  • The p53 tumor suppressor gene plays a critical role in preventing cancer.
  • Germline inactivation of p53 leads to Li-Fraumeni syndrome in humans, a rare inherited cancer predisposition.
  • Studying p53 function in vivo is essential for understanding cancer development.

Purpose of the Study:

  • To investigate the role of p53 in cancer development and progression using a mouse model.
  • To establish a preclinical tool for evaluating carcinogens, teratogens, and therapeutic agents.
  • To analyze the impact of p53 loss on tumor formation and growth dynamics.

Main Methods:

  • Gene targeting to create p53 germline inactivation in mice.
  • Phenotypic analysis of p53 null (p53-/-) and heterozygous (p53+/-) mice.
  • Tumor development monitoring and characterization.

Main Results:

  • p53 null mice exhibit significantly accelerated tumor development (average 4.5 months).
  • p53 heterozygous mice show a higher incidence of tumors by 18 months compared to wild-type.
  • p53-deficient mice provide a valuable platform for studying tumor progression.

Conclusions:

  • p53-deficient mice serve as a robust model for Li-Fraumeni syndrome and inherited cancer predisposition.
  • These mice are instrumental in understanding the in vivo functions of p53 in cancer suppression.
  • The p53 mouse model offers significant potential for preclinical assessment of cancer-related agents and therapies.

Related Experiment Videos